Ocuphire Pharma Results Presentation Deck

RM 22 Nyxol Product Candidate Profile Novel Alpha 1/2 Blocker Eye Drop for Refractive Indications (505(b)(2) Pathway) Nyxol: Phentolamine 0.75% Ophthalmic Solution Preservative Free, EDTA Free, and Stable Efficacy Data Safety Data Improving Vision ↓ Pupil Size (moderate miotic) ↑ Contrast Sensitivity (night) ↑ Near Visual Acuity (light/dark) ↑ Distance Visual Acuity No Systemic Effects No Changes in Blood Pressure No Changes in Heart Rate Tolerated Topical Effects Mild / Transient / Reversible Eye Redness IOP Unchanged or Decreased ↓ Intraocular Pressure (IOP) at Normal Baseline Chronic daily dosing of Nyxol at bedtime demonstrated no significant daytime redness and durability of effects for more than 24 hours Ocuphire PHARMA

View entire presentation